IRIS
RUSSO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.337
AS - Asia 2.126
SA - Sud America 1.045
EU - Europa 495
Continente sconosciuto - Info sul continente non disponibili 189
AF - Africa 66
OC - Oceania 3
Totale 6.261
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.206
SG - Singapore 968
BR - Brasile 798
VN - Vietnam 629
CN - Cina 261
IT - Italia 233
DE - Germania 119
AR - Argentina 108
CA - Canada 60
EC - Ecuador 53
ID - Indonesia 53
BD - Bangladesh 44
HK - Hong Kong 41
MX - Messico 37
GB - Regno Unito 32
FR - Francia 30
IN - India 30
PY - Paraguay 25
CO - Colombia 21
IQ - Iraq 19
PL - Polonia 17
ZA - Sudafrica 17
CL - Cile 15
PK - Pakistan 13
RU - Federazione Russa 11
MA - Marocco 9
TN - Tunisia 9
AT - Austria 8
DZ - Algeria 8
EG - Egitto 8
JP - Giappone 8
PE - Perù 8
UA - Ucraina 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
ES - Italia 7
VE - Venezuela 7
CR - Costa Rica 6
FI - Finlandia 6
JM - Giamaica 6
JO - Giordania 6
KE - Kenya 6
KZ - Kazakistan 6
UZ - Uzbekistan 6
MY - Malesia 5
TR - Turchia 5
HN - Honduras 4
KG - Kirghizistan 4
NL - Olanda 4
SE - Svezia 4
GE - Georgia 3
KW - Kuwait 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
ET - Etiopia 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
NG - Nigeria 2
OM - Oman 2
SA - Arabia Saudita 2
SV - El Salvador 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AO - Angola 1
BH - Bahrain 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GH - Ghana 1
GN - Guinea 1
IE - Irlanda 1
KH - Cambogia 1
KR - Corea 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 6.074
Salva come PNG Salva come JPEG
Città #
Dallas 857
Singapore 257
Ashburn 249
Ho Chi Minh City 241
Council Bluffs 184
Hanoi 148
Beijing 127
San Jose 107
Falkenstein 105
Milan 73
Los Angeles 69
São Paulo 65
New York 62
Santa Clara 56
Rome 42
Hong Kong 41
Rio de Janeiro 35
Buffalo 30
Orem 29
Haiphong 24
Guayaquil 23
Assago 20
Biên Hòa 19
Curitiba 17
Da Nang 16
Mexico City 16
Warsaw 16
Montreal 14
Philadelphia 14
Toronto 14
Charlotte 13
Naples 13
Quito 13
Asunción 12
Brasília 12
Houston 12
Hải Dương 12
Porto Alegre 12
London 11
Ninh Bình 11
Austin 10
Buenos Aires 10
Figino 10
Laurinburg 10
Lấp Vò 10
Manaus 10
Princeton 10
Salvador 10
Turin 10
Brooklyn 9
Campinas 9
Chennai 9
Chicago 9
Dhaka 9
Ha Long 9
Phoenix 9
Thái Bình 9
Bogotá 8
Guarulhos 8
Jundiaí 8
Osasco 8
Belo Horizonte 7
Cape Town 7
Fortaleza 7
Johannesburg 7
Maceió 7
Nova Iguaçu 7
Richmond 7
Amman 6
Caracas 6
Denver 6
Helsinki 6
Jakarta 6
Lahore 6
Las Vegas 6
Mumbai 6
New Braunfels 6
Okmulgee 6
Santiago 6
Santo André 6
Sumaré 6
Tashkent 6
Tokyo 6
Atlanta 5
Bauru 5
Blumenau 5
Boston 5
Córdoba 5
Manchester 5
Montevideo 5
Nairobi 5
Nanjing 5
North Kansas City 5
Nuremberg 5
Pasadena 5
Poplar 5
Quảng Ngãi 5
São Bernardo do Campo 5
Tampa 5
Thái Nguyên 5
Totale 3.509
Salva come PNG Salva come JPEG
Nome #
117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients. 574
Expression of Membrane Targets for Therapeutics in RET-Positive Non–Small Cell Lung Cancer 74
New strategies to overcome BRAF resistance in melanoma: extended BRAF or BRAF/MEK inhibition? A pooled analysis. 69
1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 67
Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. 67
31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients 65
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. 65
Impact of maintenance Pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: a single institution experience. 61
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database 61
Baseline Absolute Neutrophil Count (ANC), derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Platelet-to-Lymphocyte Ratio (PLR) and outcome in Non Small Cell Lung Cancer (NSCLC) treated with Nivolumab or Docetaxel: a preliminary analysis. 60
Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis. 60
55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. 58
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 58
Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology. 57
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance 54
Impact of germline Methylenetetrahydrofolate Reductase (MTHFR) polymorphisms on Pemetrexed-based therapies In thoracic malignancies: a pilot study. 54
Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis. 53
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non small cell lung cancer (NSCLC) 52
Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met? 52
Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer. 52
Treatment Toxicity 51
PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients. 50
The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis 49
Immune-Oncology Gene Expression Profiles allow lung cancer patients' stratification and identification of responders to immunotherapy. 49
HER2 Mutations in Non–Small Cell Lung Cancer: A Herculean Effort to Hit the Target. 47
Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study 46
Baseline markers of inflammation and outcome with Nivolumab in pretreated Non Small Cell Lung Cancers: a retrospective study. 46
Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study 45
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL 45
Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy 44
A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection 44
Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers. 43
The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis. 43
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 42
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. 41
How I treat ALK-positive non-small cell lung cancer 41
Brave new world of cfDNA-omics for early cancer detection. 41
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study 40
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 40
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 39
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer 38
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 38
Activity of EGFR tyrosine kinase inhibitors (TKIs) in brain metastases from Non Small Cell Lung Cancer (NSCLC) according to the EGFR mutational status: a survival analysis. 38
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 37
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer 37
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. 37
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists - INTERACTION GROUP. 37
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. 37
A New Generation of Vaccines in the Age of Immunotherapy. 36
A Potentially New Targetable Alteration for the Treatment of Lung Cancer 36
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data 36
Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities 36
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. 35
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 35
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 35
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study 35
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. 35
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care? 35
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. 34
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types 34
Liquid Biopsy from research to clinical practice: focus on Non-Small Cell Lung Cancer. 34
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 34
Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients. 34
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. 34
Application of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 34
Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021 33
Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non-Small-Cell Lung Cancer 33
Acquired resistance in oncogene-addicted non-small-cell lung cancer 33
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA 33
Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives 33
B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? 33
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. 33
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC 32
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients. 32
Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies 32
Innovation in next-generation sequencing in non-small cell lung cancer diagnostics 32
Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic spread in treatment-naïve Adenocarcinomas of the lung. 32
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 31
STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). 31
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer 31
Challenges of interpreting NGS liquid biopsy (LB) results in advanced NSCLC: Are ESCAT and OncoKB scales reliable? 31
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 30
Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR-mut+) non small cell lung cancers (NSCLCs): Correlations with clinical oucomes. 30
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. 30
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. 30
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. 29
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 29
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. 29
Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study 29
Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction–Based Testing. 29
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. 29
NSCLC and HER2: between lights and shadows 29
The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution? 29
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment. 29
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1) 29
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 28
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) 28
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question 28
Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy: Management of C797S acquired mutation 28
Emerging noncoding RNAs contained in extracellular vesicles: rising stars as biomarkers in lung cancer liquid biopsy. 28
Totale 4.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20243 0 0 0 0 0 0 0 1 0 0 1 1
2024/20259 1 0 0 0 0 1 1 0 2 3 1 0
2025/20265.518 147 446 1.153 1.119 415 207 566 468 254 229 220 294
2026/2027731 479 252 0 0 0 0 0 0 0 0 0 0
Totale 6.261